Positive outcomes for apalutamide in the treatment of mHSPC


According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. The full text of the media release is available on line.

As many of our readers will be aware, apalutamide was initially approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in 2018.

The TITAN trial enrolled 1,052 patients into an international, randomized, double-blind, placebo-controlled, Phase III study in which all patients had metastatic, hormone-sensitive prostate cancer (mHSPC) — also referred to as metastatic, castration-sensitive prostate cancer (mCSPC). Eligible patients were randomized to treatment with either

  • Standard ADT + apalutamide (the experimental arm) or
  • Standard ADT + a placebo (the control arm)

Standard ADT in this trial meant either treatment with an LHRH agonist like leuprolide acetate or a bilateral orchiectomy.

The primary endpoints of the study were radiographic progression-free survival (rPFS) and overall survival (OS). Secondary study endpoints include time to chemotherapy, time to pain progression, time to chronic opioid use, and time to skeletal-related event(s).

According to the corporate media release, the data from this study will be submitted for presentation at a future research conference (perhaps at the annual meeting of the American Society for Clinical Oncology later this year). These data will also be used to support regulatory submissions — e.g., to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) — later this year for the potential approval of apalutamide for the treatment of mHSPC. Such approvals might occur late in 2019 or early in 2020.

As yet we have no detailed information about the degree of effectiveness of the combination of ADT + apalutamide as compared to ADT + a placebo, or the relative safety of the two combinations. We will need to wait to hear more about these details.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: